Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8680271 | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | 2018 | 5 Pages |
Abstract
Ligands targeting tau for use with positron emission tomography have rapidly been developed during the past several years, enabling the in vivo study of tau pathology in patients with Alzheimer's disease and related non-Alzheimer's disease tauopathies. Several candidate compounds have been developed, showing good in vitro characteristics with respect to their ability to bind tau deposits; off-target binding, however, has also been observed. In this short commentary, we briefly summarize the available in vivo and in vitro evidence pertaining to their off-target binding and discuss the different approaches that are needed for the future development of tau positron emission tomography tracers.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Laetitia Lemoine, Antoine Leuzy, Konstantinos Chiotis, Elena Rodriguez-Vieitez, Agneta Nordberg,